Pluri (PLUR) News Today $5.17 -0.29 (-5.31%) Closing price 03:58 PM EasternExtended Trading$5.33 +0.16 (+3.09%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLUR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Reviewing Pluri (NASDAQ:PLUR) and Medicus Pharma (NASDAQ:MDCX)August 26 at 3:27 AM | americanbankingnews.comPluri Inc. director not re-elected, Nasdaq compliance cure period grantedJuly 5, 2025 | investing.comInsider Buying: Pluri Inc. (NASDAQ:PLUR) Director Purchases 976,139 Shares of StockJuly 2, 2025 | insidertrades.comAlliance Global Partners Initiates Coverage of Pluri (PLUR) with Buy RecommendationJune 2, 2025 | msn.comPluri Inc. reschedules 2025 annual meetingMay 27, 2025 | investing.comBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical TrialsMay 27, 2025 | prnewswire.comBrainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plansMay 19, 2025 | msn.comPluri Inc.: Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.May 16, 2025 | finanznachrichten.dePluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market ExpansionMay 16, 2025 | tmcnet.comPluri Inc. acquires majority stake in Kokomodo Ltd.April 30, 2025 | uk.investing.comPluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.April 28, 2025 | globenewswire.comPluri Inc. enters agreement, issues pre-funded warrantsApril 27, 2025 | investing.comUkraine gains access to Israeli anti-radiation drug amid nuclear threatsApril 21, 2025 | msn.comUkraine prepares for nuclear emergency - Israel to help save thousandsApril 21, 2025 | msn.comIn case of a nuclear event, Ukraine to use Israeli placenta-based emergency treatmentApril 20, 2025 | msn.comPluri announces USPTO issued patent covering its immune cell expansion techApril 12, 2025 | markets.businessinsider.comPluri’s immune cell expansion technologies gain patentsApril 11, 2025 | finance.yahoo.comPluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and IsraelApril 10, 2025 | finance.yahoo.comUsing cell science to fight nuclear weapons: How is Pluri revolutionizing health and food tech?March 14, 2025 | msn.comPluri announces exclusive collaboration agreement with HemafundMarch 5, 2025 | markets.businessinsider.comPluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency PreparednessMarch 5, 2025 | globenewswire.comEver After Foods and Bühler Collaborate to Scale Cultivated Meat Production and DistributionFebruary 19, 2025 | globenewswire.comPluri secures additional $3.5M investment from Merchant Adventure FundFebruary 4, 2025 | markets.businessinsider.comPluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 MillionFebruary 4, 2025 | markets.businessinsider.comPluri Strengthens Leadership Amid Strategic Board AppointmentJanuary 29, 2025 | tipranks.comPluri secures $6.5M investment, acquires 71% stake in Kokomodo for $4.5MJanuary 23, 2025 | markets.businessinsider.comPluri gets $6.5M investment from Alejandro Weinstein, enters cacao marketJanuary 23, 2025 | markets.businessinsider.comPluri Secures $6.5 Mln Investment To Buy 71% Of Kokomodo To Enter Cocao MarketJanuary 23, 2025 | markets.businessinsider.comPluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through AcquisitionJanuary 23, 2025 | globenewswire.comPluri Inc. granted extension to regain Nasdaq complianceJanuary 21, 2025 | msn.comPluri congratulates Mesoblast, CEO on FDA approval of MSC-based therapyDecember 20, 2024 | markets.businessinsider.comPluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host DiseaseDecember 19, 2024 | globenewswire.comPluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025December 10, 2024 | markets.businessinsider.comPluri Inc.'s PluriCDMO™ Nominated for CDMO of the Year Award at Advanced Therapies Awards 2025December 9, 2024 | quiverquant.comQPluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat ConcernsNovember 25, 2024 | markets.businessinsider.comBrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial ManufacturingNovember 11, 2024 | prnewswire.comPluri collaborates with Bar-Ilan University to advance cancer immunotherapyOctober 28, 2024 | markets.businessinsider.comPluri Flat on Funding From Innovation AuthorityOctober 28, 2024 | baystreet.caPluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation AuthorityOctober 28, 2024 | tmcnet.comPluri Inc. regains compliance with Nasdaq listing rulesOctober 3, 2024 | investing.comPlurilock Appoints David Kris, Former Head of the Department of Justice’s National Security Division, to Industry Advisory CouncilSeptember 16, 2024 | msn.comOgun PDP caretaker chair hails violent-free ward congressAugust 31, 2024 | msn.comPlurilock Security Inc. Reports Second Quarter Fiscal 2024 Financial ResultsAugust 31, 2024 | msn.comRAMSAY SANTE: Provisional annual results at the end of June 2024August 30, 2024 | finanznachrichten.deCell Therapy Manufacturing Market Size Projected to Reach USD 17.3 Billion by 2034, at 13.90% CAGR: Prophecy Market InsightsAugust 30, 2024 | uk.finance.yahoo.comPlurilock Engages Clear Street to Review U.S. Strategic OptionsAugust 26, 2024 | msn.comA look ahead to MK Dons' home game against Carlisle UnitedAugust 24, 2024 | msn.comMental Health Matters: Seven Tips To Better Support LGBTQ+ ProfessionalsAugust 20, 2024 | forbes.comPluri-Investissements C (0P000025S3.F)August 15, 2024 | uk.finance.yahoo.comHalf of LGBTQ+ professionals have experienced depression & few feel they can be “authentic” at workJuly 20, 2024 | msn.com Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLUR Media Mentions By Week PLUR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PLUR News Sentiment▼0.000.72▲Average Medical News Sentiment PLUR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PLUR Articles This Week▼20▲PLUR Articles Average Week Get the Latest News and Ratings for PLUR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Pluri and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Lexeo Therapeutics News Today Cybin News Today Nuvectis Pharma News Today biote News Today Greenwich LifeSciences News Today BioHarvest Sciences News Today Cardiff Oncology News Today Eledon Pharmaceuticals News Today Black Diamond Therapeutics News Today Cabaletta Bio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PLUR) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s national nightmare is hereWhile the headlines focus on global conflicts, there’s a very different crisis brewing at home. Washington has...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access